Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)

Rhea-AI Summary

Ocuphire Pharma (Nasdaq: OCUP) has announced positive Phase 2 clinical study results for phentolamine mesylate eye drops (Nyxol) in patients with night vision disturbances (NVD). The study's findings, highlighting Nyxol's safety and efficacy, were published in BMC Ophthalmology. The results contributed to the design of the Phase 3 LYNX-1 trial, which met its primary and secondary endpoints. Additionally, Ocuphire has partnered with the American Society of Ophthalmic Administrators to enhance the role of ophthalmic administrators in product adoption.

Positive

• Phase 2 study results for Nyxol published in BMC Ophthalmology indicating safety and efficacy.
• Phase 3 LYNX-1 trial met primary and secondary endpoints with statistical significance.
• Strategic partnership with the American Society of Ophthalmic Administrators to promote ophthalmic product adoption.

Negative

• None.

FARMINGTON HILLS, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that the positive results in night vision disturbances (NVD) patients from its earlier and first Phase 2 study evaluating the safety and efficacy of phentolamine mesylate eye drops (Nyxol) have been peer-reviewed and published in BMC Ophthalmology.

“High quality clinical data and scientific communications are core strengths at Ocuphire,” said Mina Sooch, Founder and CEO. “The growing body of scientific publications across our front and back of the eye candidates, Nyxol and APX3330, respectively, continues to validate the differentiated MOAs to the medical and scientific community. These Phase 2 data were used to inform the design of the Phase 3 LYNX-1 trial in NVD that met its primary endpoint and key secondary endpoints with statistically significance. We would like to thank Dr. Marguerite McDonald, MD for her early contributions to the development of Nyxol in Night Vision Disturbances (NVD), a challenging condition for tens of millions of patients. There are currently no treatment options for physicians, and Nyxol is the only development stage drug candidate pursuing NVD as an indication for potential regulatory approval."

A manuscript titled “A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances,” has been published in BMC Ophthalmology for clinical trial NCT04004507 and reported Nyxol was well-tolerated and effectively reduced pupil size with improvements in contrast sensitivity and visual acuity.

In addition, Ocuphire is announcing the Strategic Business Partnership with the American Society of Ophthalmic Administrators (ASOA), the largest ophthalmic practice professionals network in eyecare. “Most companies underappreciate the administrative members of the ophthalmic practice and work directly with the physicians,” said Mina Sooch. “In addition to the physicians, we believe the ophthalmic administrators play a key role in engaging with patients and influencing the success of new product adoption. We are pleased to be the first company to join the newly created category for emerging companies.”

About Ocuphire Pharma

Ocuphire is a publicly traded (Nasdaq: OCUP), clinical-stage, ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of refractive and retinal eye disorders. For more information about Ocuphire and its clinical trials, visit www.ocuphire.com

Ocuphire Contacts

Mina Sooch, President & CEO 
Ocuphire Pharma, Inc. 
ir@ocuphire.com 

Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com 

Bret Shapiro
Core IR
brets@coreir.com 

FAQ

What were the results of Ocuphire Pharma's Phase 2 study for Nyxol?

The Phase 2 study for Nyxol showed positive results, indicating safety and efficacy in treating night vision disturbances, with findings published in BMC Ophthalmology.

What is the significance of the Phase 3 LYNX-1 trial for Nyxol?

The Phase 3 LYNX-1 trial successfully met its primary and secondary endpoints with statistical significance, reinforcing Nyxol's potential as a treatment.

When was the strategic partnership with ASOA announced?

Ocuphire Pharma announced the strategic partnership with the American Society of Ophthalmic Administrators as part of their efforts to enhance product adoption.

What is Nyxol used to treat?

Nyxol is being developed for the treatment of night vision disturbances, a condition currently lacking effective treatment options.